Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition
Abstract Elraglusib (formerly 9-ING-41) is an ATP-competitive inhibitor of glycogen synthase kinase-3β (GSK3β) undergoing clinical trials for the treatment of various cancers including non-Hodgkin lymphoma (NHL). The drug reduces proliferation of several NHL cell lines and has efficacy in xenograft...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2023-06-01
|
| coleção: | Cell Communication and Signaling |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s12964-023-01147-8 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|